tarcocimab tedromer
Generic: KSI-301·Code: KSI-301
tarcocimab tedromer: 1 clinical trial tracked.
tarcocimab tedromer evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about tarcocimab tedromer, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Three-arm Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Primary endpoint: Best corrected visual acuity (BCVA)
InterventionalRandomizedquadruple675 targetStarted 2024-08Completion 2027-0850 sites · United StatesKodiak Sciences Inc